The earnings call highlights significant revenue growth and strategic acquisitions, but also faces challenges with increasing expenses and adjusted revenue expectations for VOXZOGO. The company's strong performance and future outlook are tempered by these operational challenges.

Company Guidance -

Q3 2025

During BioMarin Pharmaceuticals' second quarter 2025 conference call, the company announced significant financial and strategic achievements. BioMarin reported a robust 16% year-over-year increase in total revenues for Q2 and revised its full-year 2025 guidance upwards for total revenues to a range of $3.125 billion. The company highlighted strong performances from key products, with VOXZOGO revenues rising 20% to $221 million and enzyme therapies generating $555 million, a 15% increase. Additionally, non-GAAP diluted earnings per share surged to $1.44, reflecting a growth rate more than three times that of revenue growth. BioMarin's non-GAAP operating margin guidance for 2025 has been raised to between 33% and 34%. The company also shared updates on its pipeline, including plans to advance BMN 333 to a registrational Phase II/III study and anticipates pivotal data readouts for BMN 401 in 2026.

Double-Digit Revenue Growth

BioMarin achieved a 16% year-over-year revenue growth in Q2 2025, driven by strong global demand and new patient starts.

VOXZOGO Revenue Increase

VOXZOGO revenue increased 20% year-over-year to $221 million, primarily due to global expansion efforts.

Enzyme Therapies Growth

Enzyme Therapies revenue rose 15% year-over-year to $555 million, highlighting strong demand across regions.

Improved Profitability

BioMarin raised its full year 2025 guidance, expecting non-GAAP operating margin between 33% and 34%, and non-GAAP earnings per share between $4.40 and $4.55.

Successful Acquisition

BioMarin completed the acquisition of Inozyme, enhancing its enzyme therapies portfolio, with pivotal data for BMN 401 expected in 2026.

BioMarin Pharmaceutical (BMRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BMRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	0.86 / -	0.55	―	―	―
Aug 04, 2025	2025 (Q2)	0.86 / 1.23	0.55	123.64% (+0.68)
May 01, 2025	2025 (Q1)	0.71 / 0.95	0.46	106.52% (+0.49)
Feb 19, 2025	2024 (Q4)	0.53 / 0.64	0.11	481.82% (+0.53)
Oct 29, 2024	2024 (Q3)	0.53 / 0.55	0.21	161.90% (+0.34)
Aug 05, 2024	2024 (Q2)	0.36 / 0.55	0.29	89.66% (+0.26)
Apr 24, 2024	2024 (Q1)	0.31 / 0.46	0.27	70.37% (+0.19)
Feb 22, 2024	2023 (Q4)	0.20 / 0.11	0	―
Nov 01, 2023	2023 (Q3)	0.22 / 0.21	-0.04	625.00% (+0.25)
Jul 31, 2023	2023 (Q2)	0.21 / 0.29	0.15	93.33% (+0.14)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BMRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$60.31	$61.93	+2.69%
May 01, 2025	$62.71	$62.03	-1.08%
Feb 19, 2025	$65.61	$68.73	+4.76%
Oct 29, 2024	$69.91	$66.68	-4.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.